Cerus corporation (CERS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating activities
Net loss

-71,244

-57,564

-60,585

-62,906

-55,868

-38,755

-43,337

-15,917

-16,982

-16,911

-24,135

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,403

1,445

1,811

1,817

1,699

1,415

745

744

922

853

866

Stock-based compensation

13,312

10,394

9,355

8,065

6,730

5,153

3,268

2,541

1,850

1,828

2,046

Non-cash operating lease cost

1,580

-

-

-

-

-

-

-

-

-

-

Changes in valuation of warrant liability

-

-

-

-

-3,566

-7,708

15,099

-2,059

486

39

63

Non-cash interest expense

386

1,248

551

1,017

508

131

25

-20

-5

152

0

Non-cash deferred manufacturing and development expense

-

-

-

-

434

-

-

-

-

-

-

Impairment of long-term investment in related party

-

-

-

-

-

-

-

-

-

-

2,340

Gain from operating settlement

-

-

-

-

-

-

-

-

-

-

1,381

Gain on non-controlling equity interest

-

-

-

-

-

-

-

-

-

315

0

Loss on disposal of property and equipment

-15

-5

-

-

-

-3

-56

0

-

-

-102

Deferred income taxes

-

-

-

28

7

26

27

62

-

0

-

Impairment of long-lived assets

-

-

-

150

0

0

-

-

-

-

-

Non-cash tax expense from realized gain on available-for-sale securities

-

-

3,825

-

-3,825

-

-

-

-

-

-

Gain on sale of investment in marketable equity securities

-

-

3,466

750

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

8,130

-3,663

5,547

1,074

301

-632

1,681

-1,652

1,304

1,167

-696

Inventories

6,043

-806

2,092

1,781

-3,991

-3,033

1,813

3,740

601

-2,066

-3,402

Other assets

-1,787

2,744

-1,107

-1,327

-1,379

1,655

-286

1,663

13

-99

-97

Accounts payable

5,017

5,683

2,487

3,261

-3,866

-973

-1,512

2,506

1,450

-1,193

102

Accrued liabilities and other non-current liabilities

1,295

6,046

-626

1,330

1,359

-1,382

2,121

1,971

-336

569

1,368

Accrued restructuring

-

-

-

-

-

-

-

-

-

-113

113

Manufacturing and development obligations

-6,288

-266

680

-3,568

-

-

-

-

-

-

-

Deferred product revenue

72

38

265

-445

190

269

104

-34

-137

-97

-100

Net cash used in operating activities

-65,838

-31,246

-52,235

-53,529

-51,129

-39,811

-26,662

-13,917

-15,632

-14,268

-14,547

Capital expenditures

8,935

1,144

353

563

722

2,106

663

81

158

1,692

191

Proceeds from sale of fixed assets

-

-

-

-

-

25

-

-

-

-

-

Purchases of investments

43,907

80,701

68,792

82,811

90,407

25,981

30,146

0

-

-

499

Sales of investments

-

-

-

-

-

-

-

-

-

88

499

Proceeds from maturities and sale of investments

81,027

37,997

69,566

63,450

92,645

24,915

1,631

287

666

1,545

9,477

Proceeds from sales of certain other assets

-

-

-

-

-

-

-

-

-55

11

-37

Restricted cash

-

-

-

-

-

-

14

1

-

-

-

Net cash (used in) provided by investing activities

28,185

-43,848

421

-19,924

1,516

-3,147

-29,192

205

563

-70

9,323

Financing activities
Net proceeds from equity incentives

3,210

7,848

2,428

3,068

12,767

11,592

1,684

332

143

370

78

Net proceeds from public offerings

26,931

85,036

30,197

22,121

75,300

18,488

61,425

14,226

9,273

19,291

12,135

Proceeds from revolving line of credit

-

-

-

-

-

-

-

-

-

-

0

Proceeds from debt, net of discount

-

-

-

-

-

-

-

-

4,910

4,811

0

Net payment on revolving line of credit

-

-

-

-

-

-

-

-

-

0

-

Proceeds from landlord provided leasehold incentives

-

-

-

-

-

-

-

-

-

-1,561

0

Net proceeds from revolving line of credit

5,017

-

-

-

-

-

-

-

2,300

0

-

Proceeds from loans

39,433

-

30,000

-

10,000

9,848

3,102

1,810

-

-

-

Repayment of debt

31,104

133

19,625

622

113

3,474

7,568

1,457

-

-

-

Non-cash settlement of warranty claim

-

-

-

-

-

-

1,272

-

-

-

-

Unpaid manufacturing and development obligation

-

-

-

-

7,051

-

-

-

-

-

-

Net cash provided by financing activities

43,487

92,751

43,000

24,567

97,954

36,454

58,643

14,911

11,618

25,999

12,208

Net (decrease) increase in cash, cash equivalents and restricted cash

5,834

17,657

-8,814

-48,886

48,341

-6,504

2,789

1,199

-3,451

11,661

6,984

Payments on debt, revolving line of credit and landlord provided leasehold incentives

-

-

-

-

-

-

-

-

5,008

34

5

Supplemental disclosure of cash flow information:
Cash paid for interest

3,077

2,728

2,034

1,366

1,087

563

294

460

1,024

600

4

Non-cash conversion of preferred stock to common stock

-

-

-

-

-

-

-

9,496

-

0

-

Common stock issued in connection with the acquisition of certain assets of BioOne

-

-

-

-

-

-

-

-

-

3,423

0

Cash paid for income taxes

229

254

160

157

153

177

146

162

125

114

-

Non-cash investing activities:
Non-cash purchases of capital expenditures

2,949

2,222

-

-

-

-

-

-

-

-

-